Longevity & cellular health

"Longevity" and "anti-ageing" are among the most marketed and least evidenced peptide categories. The compounds here have genuine mechanistic research behind them, but human evidence for actually slowing ageing or extending lifespan is effectively absent.

Epitalon is a synthetic tetrapeptide claimed to activate telomerase and influence the pineal gland; its evidence is dominated by a single research group, largely unreplicated, and often conflates a pineal extract with the pure peptide. MOTS-c is a mitochondrial-derived peptide with interesting metabolic and exercise-mimetic effects in cell and animal studies, but human data are limited to genetic-association observations, with no therapeutic trials of the native peptide. SS-31 (elamipretide) is the most clinically advanced: it targets mitochondrial cardiolipin and has been through many human trials, but several missed their primary endpoints, and its 2025 FDA approval is a narrow, accelerated one for the ultra-rare Barth syndrome, not for general longevity.

Conditions people ask about

Popular videos and high-claim content in this area promise to "reverse", "reset", or "cure" ageing — telomere injections, "zombie cell" clearers, gene-expression age resets, and exercise-in-a-vial mitochondrial peptides sold as a longevity stack that adds years to your life. That framing is not supported. No compound on this site is an approved treatment for any condition below, and the dramatic "reversal" claims lack controlled human evidence. The notes below answer the searches people actually run, honestly. Aging and age-related disease are matters for a licensed clinician and a proper diagnosis — a research peptide is not a substitute for one, and "reversal" language is not backed by controlled human evidence.

Biological aging / "longevity"

What's claimed: that a peptide stack can slow, "reverse", or "reset" biological age — telomere-lengthening injections, senescent-cell ("zombie cell") clearers, gene-expression "age resets", and mitochondrial "exercise mimetics" marketed together as a protocol that extends lifespan.

The evidence reality: no compound in this inventory is an approved anti-aging or lifespan-extension treatment, and none can be — the FDA does not recognise aging itself as a disease, so drugs are only ever approved for specific conditions, never for "longevity" [Human]. Almost all of the dramatic claims rest on cell-culture and rodent data, or on a single Russian research group's small, unblinded, never-Western-replicated mortality studies; there is no controlled human evidence that any of these compounds extends human lifespan or "reverses" biological age. Where a mitochondrial peptide has reached regulatory approval, it was a narrow, conditional approval for a specific rare disease, not for aging. This is a matter for a licensed clinician and a proper diagnosis — a research peptide is not a substitute.

Compounds discussed in this context:

• Epitalon — a synthetic pineal tetrapeptide (a Khavinson "bioregulator") marketed as a telomerase-activating longevity peptide. Telomere lengthening is real in human cell lines [In vitro], and it comes out of a Russian peptide-bioregulator school that reports long-follow-up mortality reductions in elderly cohorts — but that evidence is older, small, and dominated by one research group, largely unreplicated to Western Phase 3 standards [Human, low quality]. Not approved for aging anywhere; much of the strongest longevity signal traces to the pineal extract (epithalamin) it was derived from rather than the pure synthetic peptide.
• Thymalin — a thymic bioregulator preparation from the same Russian research programme; it appears in a disputed Neuroendocrinology Letters (2003) study that followed ~266 elderly people over 6–8 years and reported reduced mortality, with the largest reduction when combined with the pineal preparation epithalamin [Human, low quality — small, unblinded, single-lab, not replicated]. Discussed for immune "restoration" with age. Not FDA- or EMA-approved for longevity; the wider Khavinson family is marketed similarly but rests on the same limited evidence base.
• SS-31 (elamipretide) — a mitochondria-targeting peptide, and the most clinically advanced compound here: it has been through many human trials, and in September 2025 the FDA granted it accelerated approval (as elamipretide HCl, brand Forzinity) — but that approval is narrow and conditional, only to improve muscle strength in the ultra-rare Barth syndrome, resting on an intermediate endpoint and subject to confirmatory study [Human]. Several of its randomised trials — in mitochondrial myopathy, heart failure, and dry AMD — missed their primary endpoints. It is not an approved anti-aging, longevity, or general heart-failure drug, and community framing of it as a general "anti-aging" mitochondrial peptide outruns the actual, disease-specific evidence.
• MOTS-c — a mitochondrial-derived peptide whose endogenous levels rise with exercise and fall with age, and which is associated with longevity in some human observational data [Human, associational]. Late-life dosing improved physical capacity in mice [Animal]. Marketed as an "exercise mimetic" for healthspan, but there are no controlled human trials of MOTS-c injection for aging outcomes.
• Humanin — a mitochondrial-derived peptide studied for cytoprotection; endogenous levels decline with age, and human data are largely observational [Human, associational]. Cited in longevity discussions for cellular stress resistance, but the evidence is largely mechanistic and observational — there are no completed human therapeutic trials of administered humanin, and none showing it slows aging or extends lifespan.
• NAD+ — NAD+ (and precursors like NMN/NR) is the community's central "longevity" molecule, though it is a redox coenzyme, not a peptide. Supplementation reliably raises blood NAD+ and appears well tolerated in small human trials [Human], and extends lifespan in mice [Animal] — but there is no human evidence it extends lifespan or reverses aging, and metabolic-benefit results in people are small and inconsistent. IV/injectable NAD+ is not FDA- or EMA-approved; oral NAD+ and its precursors are sold as unapproved dietary supplements with very little human efficacy data for aging itself.
• GHK-Cu — a copper tripeptide famous for a gene-expression analysis suggesting it shifts aged-cell expression toward younger patterns [In vitro]. Its real human evidence is for skin — collagen density, wound healing [Human] — not systemic longevity; the "resets hundreds of aging genes" story is a cell/database finding, and there is no controlled human trial of GHK-Cu as a lifespan or biological-age intervention.
• FOXO4-DRI — a designed senolytic peptide meant to clear "zombie" (senescent) cells by disrupting the FOXO4–p53 interaction. It reduced senescent-cell burden and restored some tissue function in mice and cell culture [Animal, In vitro], but as of 2026 there are no published human trials [no controlled human evidence]. Purely preclinical; the senolytic field's human data comes from other agents, not this peptide.
• 5-Amino-1MQ — an NNMT inhibitor (a small molecule, not a peptide) marketed as a metabolic / "exercise-mimetic" longevity compound. In diet-induced obese mice it reduced body weight and fat mass [Animal]; the whole evidence base is mechanistic and rodent/cell only [Animal, In vitro], with no published human trials and no human PK data for aging or metabolic outcomes [no controlled human evidence].
• SLU-PP-332 — an ERR agonist (a small molecule, not a peptide) promoted as "exercise in a pill" for endurance and healthspan. It improved endurance and metabolic markers and cut fat mass in mice [Animal], but it is very new, animal-only, with no human safety or efficacy data [no controlled human evidence] — sold strictly as a research chemical.